000100:KRXYuhan Corporation Analysis

Yuhan Corp. is trading at 99,300 KRW, well below its 20‑day (105,545), 50‑day (107,898) and 200‑day (112,854) moving averages, signaling a bearish technical backdrop. The MACD is in a bearish configuration and the RSI sits at 40.6, indicating limited upward momentum. Volatility is elevated at ~54% (30‑day) while beta remains modest (0.57), suggesting price swings are pronounced but less correlated with the broader market. The stock faces a support level near 91,600 and resistance around 114,500, with the current price positioned mid‑range. Fundamental metrics are weak: revenue contracted -4.8%, operating margin is only 3.9%, and ROE lingers at 2.4%. The forward P/E of 30.2 exceeds the industry average of 26.2, implying the market may be overpricing the earnings outlook. A discounted cash‑flow model places fair value near 19,930 KRW, a stark contrast to the current price, further underscoring potential overvaluation.
Dividend yield is modest at 0.6% with a payout ratio of 54.8%, but free cash flow is negative and debt‑to‑equity is high at 15.5, raising concerns about dividend sustainability. The company’s cash pile is sizable yet offset by substantial debt, and earnings growth appears stagnant. Given the bearish technicals, inflated valuation multiples, and balance‑sheet pressures, the near‑term outlook is cautious, while the longer‑term case is further weakened by limited growth prospects and regulatory headwinds in the specialty drug sector.